Artivion, Inc. (AORT) Q2 2025 Earnings Call Transcript

Artivion, Inc. (AORT) reported strong Q2 2025 results, with constant currency revenue increasing over 14% to $113 million and adjusted EBITDA surging 33% year-over-year to $24.8 million, reflecting a 300 basis point margin improvement. This performance was driven by exceptional 24% growth in On-X sales, buoyed by new clinical data and cross-selling opportunities from the U.S. launch of AMDS, which propelled stent graft revenue up 22%. The company also significantly strengthened its balance sheet by retiring approximately $100 million in convertible debt, reducing net leverage from 4.1 to 2.2. Consequently, Artivion raised its full-year 2025 constant currency revenue growth guidance to 12-14% and adjusted EBITDA to $86-91 million, signaling confidence in sustained momentum from its product portfolio and pipeline advancements, including the IDE approval for Arcevo LSA.

Analysis

Artivion delivered a robust second quarter for 2025, demonstrating significant acceleration in both revenue and profitability. The company reported total constant currency revenue growth of over 14% to $113 million and a 33% year-over-year increase in adjusted EBITDA to $24.8 million, expanding adjusted EBITDA margins by approximately 300 basis points to 21.9%. This performance was driven by exceptional growth in its core franchises: On-X revenues surged 24% and stent graft revenues grew 22% on a constant currency basis. The On-X growth is attributed to continued market share gains, favorable clinical data, and a notable cross-selling synergy from the U.S. launch of the AMDS device. The AMDS launch itself is progressing well, with management noting meaningful sequential revenue growth and positive physician feedback, reinforcing confidence in penetrating the estimated $150 million market opportunity. Furthermore, Artivion significantly strengthened its balance sheet by retiring nearly $100 million in convertible notes, reducing its net leverage ratio from 4.1x to 2.2x. This financial discipline, coupled with key pipeline advancements such as the IDE approval for its Arcevo LSA trial, prompted management to raise the midpoint of its full-year 2025 guidance for both revenue (now 12-14% CC growth) and adjusted EBITDA (now $86-$91 million).

Key Decisions for Investors

• Investors should recognize the accelerating top-line momentum, driven by the synergistic launch of AMDS and robust On-X demand, which underpins the company's raised full-year revenue and EBITDA guidance.
• Monitor the company's ability to deliver on its goal of growing adjusted EBITDA at twice the rate of revenue, as the increasing contribution from the higher-margin AMDS product is a key driver for future profitability.
• Consider the significantly de-risked financial profile following the retirement of convertible debt and the reduction of net leverage to 2.2x, which provides a stable foundation for funding pipeline initiatives without near-term dilution risk.
• Closely track execution on key pipeline catalysts, including the sequential revenue ramp of AMDS in the U.S. and the initiation of the Arcevo LSA pivotal trial by year-end, as these represent substantial future market opportunities.